Trelagliptin succinate

Trelagliptin succinate Chemische Eigenschaften,Einsatz,Produktion Methoden

Beschreibung

Similar to omarigliptin, trelagliptin succinate (XIX) is a highly selective, orally delivered inhibitor of DPP-4 developed by Takeda Pharmaceuticals and approved in Japan in March 2015 for the treatment of type 2 DM. Interestingly, trelagliptin is structurally similar to alogliptin, a DPP-4 inhibitor also marketed by Takeda and described in our 2010 review, differing only in the presence of a fluorine in the 5-position of the cyanobenzyl moiety. Both trelagliptin and alogliptin are potent inhibitors of DPP-4, with IC50s of 1.3 and 5.3 nM, respectively. Notably, while similar drugs are dosed once daily, trelagliptin is the first DPP-4 inhibitor approved for onceweekly dosing. Kinetic analysis has revealed that trelagliptin is a substrate-competitive, reversible, slow-binding inhibitor (t1/2 for dissociation = ca. 30 min) of DPP-4, although the dissociation time is insufficient to explain its long-acting effects. In a phase III trial, once-weekly trelagliptin (100 mg) showed similar efficacy and safety to once-daily alogliptin (25 mg) in patients with type 2 DM inadequately controlled by diet and exercise. The medicinal chemistry discovery of trelagliptin and alogliptin as well as reviews of this class of compounds have been published.

Verwenden

Trelagliptin succinate (SYR-472) is a selective, long acting dipeptidyl peptidase-4 (DPP-4) inhibitor. An antidiabetic agent.
Orally active DPP-4 inhibitor that produces clinically and statistically significant improvements in glycaemic control in patients with type 2 diabetes. SYR472 has a long duration of action and is well tolerated in clinical studies.

Clinical Use

Trelagliptin (SYR-472), a novel dipeptidyl peptidase-4 inhibitor used for the treatment of type 2 diabetes mellitus. Trelagliptin (as the salt Trelagliptin succinate) was approved for use in Japan in March 2015. Takeda, the company that developed Trelagliptin, chose to not get approval for the drug in the USA and EU.

Trelagliptin succinate Upstream-Materialien And Downstream Produkte

Upstream-Materialien

Downstream Produkte

Trelagliptin succinate Anbieter Lieferant Produzent Hersteller Vertrieb Händler.

Firmenname	Telefon	E-Mail	Land	Produktkatalog	Edge Rate
Huadong Medicine (Xi'an)Bodyguard Pharmaceutical Co.,Ltd.	+86-029-86185165 +8618629664246	guoyuan@eastchinapharm.com	China	1615	58
Firsky International Trade (Wuhan) Co., Ltd	+8615387054039	admin@firsky-cn.com	China	436	58
Hangzhou ICH Biofarm Co., Ltd	+undefined8613073685410	sales@ichemie.com	China	985	58
Zibo Hangyu Biotechnology Development Co., Ltd	+86-0533-2185556 +8617865335152	Mandy@hangyubiotech.com	China	11013	58
Shaanxi TNJONE Pharmaceutical Co., Ltd	+86-13474506593 +86-13474506593	sarah@tnjone.com	China	775	58
Capot Chemical Co.,Ltd.	571-85586718 +8613336195806	sales@capotchem.com	China	29797	60
Beijing Cooperate Pharmaceutical Co.,Ltd	010-60279497	sales01@cooperate-pharm.com	CHINA	1811	55
Henan Tianfu Chemical Co.,Ltd.	+86-0371-55170693 +86-19937530512	info@tianfuchem.com	China	21695	55
Hangzhou FandaChem Co.,Ltd.	008657128800458; +8615858145714	fandachem@gmail.com	China	9352	55
Nanjing ChemLin Chemical Industry Co., Ltd.	025-83697070	product@chemlin.com.cn	CHINA	3012	60

1029877-94-8()Verwandte Suche:

---

• Trelagliptin Succinate (SYR-472)
• SYR 111472 succinate
• SYR-472 succinate
• SYR-472 Trelagliptin succinat
• Trelagliptin succinate(SRY-472)
• Trelagliptin succinate SYR 111472 succinate
• SRY-472
• Telagliptin Succinate
• Trelagliptin succinate, >=98%
• Butanedioic acid, compd. with 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-4-fluorobenzonitrile (1:1)
• (R)-2-((6-(3-Aminopiperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)methyl)-4-f
• Trelagliptin Succinate API
• Trelagliptin (succinate)
• SYR 472 succinate
• SYR472 succinate
• Triglitastat succinate
• (R)-2-[[6-(3-Amino-1-piperidyl)-3-methyl-2,4-dioxo-1,2,3,4-tetrahydro-1-pyrimidinyl]methyl]-4-fluorobenzonitrile Succinate
• Trelagliptin succinate high quality Cas number：1029877-94-8
• CS-924
• SYR-472 SUCCINATE; SYR472 SUCCINATE; SYR 472 SUCCINATE
• Trelagliptin succinate - SYR 111472 succinate | SYR 472
• TrelChemicalbookagliptinsuccinate
• Trelagliptin Impurity 81
• SYR-472 succinate. Trelagliptin
• Trelagliptin succinate ISO 9001：2015 REACH
• Troglitinesuccinate
• relagliptin succinate
• Troxagliptin succinate
• Trelagliptin succinat
• Trogliptin succinate
• Benzoicacid,4-hydroxy-3,11-dimethoxy-
• 2-amino-1-(8-bromophenyl)ethanol
• 2-[[6-[(3R)-3-Aminopiperidin-1-yl]-3-methyl-2,4-dioxopyrimidin-1-yl]methyl]-4-fluorobenzonitrile,butanedioicacid
• SYR-472
• 2-[[6-[(3R)-3-aminopiperidin-1-yl]-3-methyl-2, ,butanedioic acid
• chloro-bis-methylsulfanyl-borane
• 1029877-94-8
• 1029877-94-0
• 29877-94-8
• C18H20FN5O2C4H6O4
• C22H26FN5O6
• Trelagliptin
• Inhibitors
• antidiabetic
• API
• 1029877-94-8